Literature DB >> 87268

Pulmonary toxicity of antineoplastic drugs.

J K Willson.   

Abstract

Drug-induced pulmonary disease is an infrequent, but clinically significant, toxic manifestation of antineoplastic drug therapy. Pulmonary toxicity has been associated primarily with bleomycin therapy but also has been described with busulfan, cyclophosphamide, methotrexate, and the nitrosoureas. Cytotoxic drug-induced pulmonary disease is characterized by an insidious and nonspecific presentation. The common pathologic process of a fibrosing alveolitis follows a variety of toxic mechanisms associated with the chemotherapeutic agents. The importance of close clinical monitoring is emphasized by the necessity for early withdrawal of the drug in order to halt or reverse potentially lethal pulmonary disease. At the same time, the nonspecific nature of the lung disease and the multitude of potential insults to the lung in a cancer patient make an early aggressive evaluation mandatory. A lung biopsy is almost always indicated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 87268

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Low dose methotrexate pneumonitis in rheumatoid arthritis.

Authors:  S Louie; G A Lillington
Journal:  Thorax       Date:  1986-09       Impact factor: 9.139

Review 3.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Treatment of small cell lung carcinoma in association with cryptogenic fibrosing alveolitis.

Authors:  J R Lipton; J Winstanley; K Carroll; J J Mould; N Thatcher
Journal:  Postgrad Med J       Date:  1982-03       Impact factor: 2.401

5.  Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.

Authors:  Jason N Barreto; Carrie A Thompson; Patrick M Wieruszewski; Amanda G Pawlenty; Kristin C Mara; Ashley L Potter; Pritish K Tosh; Andrew H Limper
Journal:  Leuk Lymphoma       Date:  2020-07-05

6.  Taurine and N-Bromotaurine in Topical Treatment of Psoriasis.

Authors:  Anthony M Kyriakopoulos; Markus Nagl; Ramesh C Gupta; Janusz Marcinkiewicz
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.

Authors:  B A Teicher; J S Lazo; W W Merrill; A E Filderman; C M Rose
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

Authors:  A M Gillespie; P C Lorigan; C R Radstone; J C Waterhouse; R E Coleman; B W Hancock
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.

Authors:  Julie K Dawson; Edmond Quah; Ben Earnshaw; Constanta Amoasii; Tareg Mudawi; Lisa G Spencer
Journal:  Rheumatol Int       Date:  2021-01-29       Impact factor: 2.631

10.  The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review.

Authors:  Yu Jie Chen; Ling Xiao Chen; Mei Xiang Han; Tian Song Zhang; Zhi Rui Zhou; Dian Sheng Zhong
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.